Woodline Partners LP Lowers Stock Holdings in Zai Lab Limited Unsponsored ADR $ZLAB

Key Points

• Woodline Partners LP reduced its stake in Zai Lab Limited by 31.8% in the first quarter, owning 1,201,016 shares valued at approximately $43.4 million after selling 558,781 shares.
• Insider transactions include Director William Lis selling 13,814 shares for about $492,745, resulting in a significant decrease in his shareholding.
• Zai Lab's stock is currently rated as a "Moderate Buy" by analysts, with an average target price of $56.35 following a recent consensus on its performance and outlook.

Woodline Partners LP lessened its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 31.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,201,016 shares of the company's stock after selling 558,781 shares during the period. Woodline Partners LP owned 1.09% of Zai Lab worth $43,405,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC increased its stake in shares of Zai Lab by 6.0% during the first quarter. Kingsview Wealth Management LLC now owns 9,323 shares of the company's stock worth $337,000 after acquiring an additional 529 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Zai Lab in the 4th quarter valued at approximately $29,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Zai Lab by 2.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company's stock worth $1,496,000 after purchasing an additional 1,200 shares during the period. Walleye Capital LLC raised its stake in shares of Zai Lab by 6.4% during the 1st quarter. Walleye Capital LLC now owns 22,276 shares of the company's stock worth $805,000 after buying an additional 1,338 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zai Lab by 13.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,544 shares of the company's stock valued at $453,000 after buying an additional 1,483 shares during the period. 41.65% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zai Lab

In other Zai Lab news, Director William Lis sold 13,814 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.67, for a total value of $492,745.38. Following the sale, the director owned 35,106 shares of the company's stock, valued at $1,252,231.02. This represents a 28.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rafael Amado sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $35.00, for a total transaction of $105,000.00. Following the transaction, the insider directly owned 42,178 shares of the company's stock, valued at approximately $1,476,230. This trade represents a 6.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 215,710 shares of company stock valued at $7,589,684 in the last quarter. 4.96% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Leerink Partners set a $75.00 price objective on Zai Lab and gave the stock an "outperform" rating in a report on Monday, June 30th. Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Jefferies Financial Group initiated coverage on shares of Zai Lab in a report on Monday, August 25th. They issued a "buy" rating and a $52.00 price target for the company. Finally, Citigroup reissued a "buy" rating and set a $69.00 price objective (up previously from $66.00) on shares of Zai Lab in a report on Monday, August 11th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $56.35.

Zai Lab Stock Performance

ZLAB opened at $31.33 on Tuesday. The company has a market cap of $3.50 billion, a price-to-earnings ratio of -15.36 and a beta of 1.04. Zai Lab Limited Unsponsored ADR has a one year low of $19.41 and a one year high of $44.34. The business's fifty day moving average is $35.15 and its two-hundred day moving average is $34.08.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). The business had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%. Zai Lab has set its FY 2025 guidance at EPS. On average, analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current fiscal year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.